Ondansetron
A selective 5-HT3 receptor antagonist, ondansetron blocks the serotonin signaling that triggers nausea and vomiting. It is used to prevent these symptoms after chemotherapy, radiation, and surgery. With the molecular formula C18H19N3O, it was among the first agents of its class and transformed the tolerability of cancer treatment by controlling emesis that older antiemetics could not.
A serotonin receptor antagonist preventing chemotherapy-induced and post-operative nausea and vomiting.
Molekularmasse
293,3660 g/mol
LogP
2,30
TPSA
39,80 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Arzneimittelklassen
Wirkmechanismus
Selective 5-HT3 receptor antagonist.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective 5-HT3 receptor antagonist.
2D-Struktur
Cite this structure
Embed this structure
SMILES
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
InChI
InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
Molecular Formula
C18H19N3O
HBD / HBA
- / 2
Rotierbare Bindungen
2
Schwere Atome
22
No targets recorded
Target interaction data is not yet available for this drug.
Escitalopram and ondansetron together carry dual risks: serotonin syndrome and additive QT interval prolongation, making this combination particularly dangerous.
Azithromycin and ondansetron both prolong the cardiac QT interval; their combination substantially increases the risk of torsades de pointes.
Fluconazole inhibits the metabolism of ondansetron and both drugs prolong the QT interval, creating a compounded arrhythmia risk.
Ciprofloxacin and ondansetron both prolong the QT interval; combined use raises the risk of torsades de pointes and sudden cardiac death.
Hydroxychloroquine and ondansetron both prolong cardiac repolarization via hERG blockade; concurrent use substantially elevates arrhythmia risk.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A serotonin receptor antagonist preventing chemotherapy-induced and post-operative nausea and vomiting.
Selective 5-HT3 receptor antagonist.
Key pharmacokinetic parameters for Ondansetron: Half-life: 3-5 hours.
Yes, Ondansetron is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL46. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 4595. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ondansetron"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ondansetron/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ondansetron/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ondansetron/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ondansetron"></drugfyi-drug>